ADRIAN GOTTSCHALK - 26 Jan 2022 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Role: Chief Executive Officer, Director
Signature: /s /Allan Reine, M.D., Attorney-in-Fact for Adrian Gottschalk
Issuer symbol: FHTX
Transactions as of: 26 Jan 2022
Transactions value $: $0
Form type: 4
Filing time: 28 Jan 2022, 15:26:40 UTC
Previous filing: 23 Aug 2021
Next filing: 22 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	FHTX	Common Stock						146K	26 Jan 2022	Direct
holding	FHTX	Common Stock						325K	26 Jan 2022	See Footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FHTX	Stock Option (right to buy)	Award	$0	+440K		$0.00	440K	26 Jan 2022	Common Stock	440K	$14.87	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of 300,000 shares held by the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust dated November 29, 2021, of which the Reporting Person is the trustee and sole current beneficiary, and 25,225 shares held by the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee.
F2	The option vested as to 25% of the underlying shares of common stock on January 26, 2023, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested.